Moreover, recent studies revealed that CX3CR1+CD8+T cell subsets not only precisely predicted early response in anti-PD1 therapy, but also enhanced the anti-tumor efficacy in vitro (60, 61). This evidence concerns the gene CD8A and neoplasm.